Daniel Arber to Disease Progression
This is a "connection" page, showing publications Daniel Arber has written about Disease Progression.
Connection Strength
0.166
-
Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
Score: 0.028
-
Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017 Jul 01; 148(1):49-57.
Score: 0.027
-
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res. 2017 03 15; 77(6):1261-1270.
Score: 0.027
-
Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med. 2016 Jul; 140(7):672-4.
Score: 0.025
-
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010 Aug; 85(8):600-6.
Score: 0.017
-
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol. 2009 Jun; 146(1):86-90.
Score: 0.016
-
Lymphoplasmacytic lymphoma arising in the setting of hepatitis C and mixed cryoglobulinemia. J Clin Oncol. 2007 Sep 20; 25(27):4312-4.
Score: 0.014
-
Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis. Am J Clin Pathol. 2006 Oct; 126(4):545-51.
Score: 0.013